FACE: the barefaced facts of AI potency

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053651687171715894097
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPWickerhamDLTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst199890137113889747868
   PubMed Web of Science ®Google Scholar
• BraithwaiteRSChlebowskiRTLauJGeorgeSHessRColNFMeta-analysis of vascular and neoplastic events associated with tamoxifenJ Gen Intern Med20031893794714687281
   PubMed Web of Science ®Google Scholar
• MouridsenHTBhatnagarASLetrozole in the treatment of breast cancerExpert Opin Pharmacother200561389139916013988
   PubMed Web of Science ®Google Scholar
• RieberAGTheriaultRLAromatase inhibitors in postmenopausal breast cancer patientsJ Natl Compr Canc Netw2005330931416002003
   PubMedGoogle Scholar
• GeislerJLonningPEAromatase inhibition: translation into a successful therapeutic approachClin Cancer Res2005112809282115837728
   PubMed Web of Science ®Google Scholar
• Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ GroupForbesJFCuzickJBuzdarAHowellATobiasJSBaumMEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol20089455318083636
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMATAC Trialists’ GroupResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet2005365606215639680
   PubMed Web of Science ®Google Scholar
• Breast International Group (BIG) 1–98 Collaborative GroupThürlimannBKeshaviahACoatesASA comparison of letrozole and tamoxifen in postmenopausal women with early breast cancerN Engl J Med20053532747275716382061
   PubMed Web of Science ®Google Scholar
• CoatesASKeshaviahAThürlimannBFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98J Clin Oncol20072548649217200148
   PubMed Web of Science ®Google Scholar
• BIG 1–98 Collaborative GroupMouridsenHGiobbie-HurderAGoldhirschALetrozole therapy alone or in sequence with tamoxifen in women with breast cancerN Engl J Med200936176677619692688
   PubMed Web of Science ®Google Scholar
• ThurlimannBBIG 1-98 Collaborative and International Breast Cancer Study GroupsLetrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer39th St. Gallen Symposium2009 May 7–9St. Gallen, Switzerland Abstr 0161.
   Google Scholar
• CoombesRCKilburnLSSnowdonCFIntergroup Exemestane StudySurvival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialLancet200736955957017307102
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSRandomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17J Natl Cancer Inst2005971262127116145047
   PubMed Web of Science ®Google Scholar
• GeislerJHelleHEkseDLetrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levelsClin Cancer Res2008146330633518829517
   PubMed Web of Science ®Google Scholar
• DixonJMRenshawLYoungOLetrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancerJ Clin Oncol2008261671167618375896
   PubMed Web of Science ®Google Scholar
• BaumMBuzdarAUCuzickJfor the ATAC Trialists GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trialLancet200235921312139 Erratum in: Lancet.2002360152012090977
   PubMed Web of Science ®Google Scholar
• Arimidex [package insert]. Wilmington, DE: AstraZeneca; Rev. 12/08.
   Google Scholar
• McArthurHLOlivottoIGelmonKARisk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifenBreast Cancer Res Treat200594Suppl 1S124 Abstr 3001.
   Google Scholar
• HortobagyiGNKauS-WBuzdarAUWhat is the prognosis of patients with operable breast cancer (BC) five years after diagnosis?Proc Am Soc Clin Oncol20042323 Abstr 585.
   Google Scholar
• BuzdarAUGuastallaJPNabholtzJMCuzickJATAC Trialists’ GroupImpact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trialCancer200610747248016804925
   PubMed Web of Science ®Google Scholar
• LameratoLHavstadSGandhiSJonesDChlebowskiRBreast cancer recurrence and related mortality in US pts with early breast cancerJ Clin Oncol20052316S62s Abstr 738.
   Google Scholar
• DoughtyJCMansellJMonypennyIDistant recurrence and subsequent mortality in breast cancer patients treated at 5 UK centres39th St. Gallen Symposium2009 May 7–9St. Gallen, Switzerland Abstr 0188.
   Google Scholar
• VakaetLBuyseMComparative results of two adjuvant trials comparing 5 years of an aromatase inhibitor (AI) with 5 years of tamoxifen (TAM) in postmenopausal women with early breast cancer (EBC)Breast Cancer Res Treat2006100Suppl 1S108S109 Abstr 2084.
   Google Scholar
• MauriacLKeshaviahADebledMBIG 1-98 Collaborative GroupInternational Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialAnn Oncol20071885986717301074
   PubMed Web of Science ®Google Scholar
• GligorovJAzriaDPivotXPenault-LlorcaFSpielmannMNamerMClinical impact of upfront adjuvant AI therapy on the early risk of recurrenceEur J Cancer20075Suppl209 Abstr 2089.
   Web of Science ®Google Scholar
• HoughtonJon behalf of the ATAC Trialists’ GroupInitial adjuvant therapy with anastrozole (S) reduced rates of early breast cancer recurrent and adverse events compared with tamoxifen (T) – data reported on behalf of the ATAC (‘Arimidex’, TAM, Alone or in Combination) Trialists’ groupAnn Oncol200617Suppl 9ix93 Abstr 243PD.
   Google Scholar
• HowellAForbesJCuzickJInitial adjuvant therapy with anastrozole – early and late event data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial in the hormone-responsive population39th St. Gallen Symposium2009 May 7–9St. Gallen, Switzerland Abstr 0130.
   Google Scholar
• RugoHRourkeMDranitsarisGKauraSLetrozole or anastrozole for the prevention of early recurrences in postmenopausal women with early stage breast cancer: Using number needed to treat (NNT) to compare benefitEur J Cancer Suppl20086118 Abstr 236.
   Google Scholar
• MansellJMonypennyIJSkeneAIPatterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancerBreast Cancer Res Treat2009117919819112615
   PubMed Web of Science ®Google Scholar
• RugoHSKauraSDranitsarisGThe number needed to treat to save a life: a comparison between aromatase inhibitors39th St. Gallen Symposium2009 May 7–9St. Gallen, Switzerland Poster 136.
   Google Scholar
• DhillonNKauraSDranitsarisGRugoHNumber needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC)J Clin Oncol20092715s Abstr 581.
   Web of Science ®Google Scholar
• GershanovichMChaudriHACamposDLetrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancerAnn Oncol199896396459681078
   PubMed Web of Science ®Google Scholar
• RoseCVtorayaOPluzanskaAAn open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozoleEur J Cancer2003392318232714556923
   PubMed Web of Science ®Google Scholar
• DowsettMJonesAJohnstonSRJacobsSTrunetPSmithIEIn vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancerClin Cancer Res19951151115159815951
   PubMed Web of Science ®Google Scholar
• MacNeillFAJonesALJacobsSLønningPEPowlesTJDowsettMThe influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancerBr J Cancer1992666926971419608
   PubMed Web of Science ®Google Scholar
• FuretPBatzlCBhatnagarAFrancotteERihsGLangMAromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compoundsJ Med Chem199336139314008496907
   PubMed Web of Science ®Google Scholar
• MonnierARefining the postmenopausal breast cancer treatment paradigm: the FACE trialExpert Rev Anticancer Ther200661355135917069521
   PubMed Web of Science ®Google Scholar
• de BoerRSrBurrisHAMonnierAon behalf of the H2H trial steering committeeThe Head to Head trial: Letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancerJ Clin Oncol20062418s582s Abstr 10672
   Google Scholar
• NCIC Clinical Trials GroupExemestane or anastrozole in treating postmenopausal women who have undergone surgery for primary breast cancer http://clinicaltrials.gov/ct2/show/NCT00066573. Accessed 2010 Jun 7.
   Google Scholar